The Mentors-in-Residence Program (MIR)
Each of our FastForward members is paired with one or more mentors who have successfully built, sold and invested in startup companies. These Mentors-In-Residence (MIRs) operate under nondisclosure agreements and share their business and technical expertise with FastForward startups.
Interested in becoming a mentor-in-residence? Contact Megan Wahler (email@example.com).
John H. Cammack is Managing Partner of Cammack Associates, which specializes in early stage investing in enterprises advancing brain fitness, business services and educational attainment. Representative investments include Curiosityville, Moodlerooms, Allovue, Calvert Education Services, UnboundConcepts, ReifyHealth, Interaxom, eMindful, Pear Therapeutics, Fusiform, Cognisens and Happlify.
From 1991 to 2009, Cammack was a senior executive at T. Rowe Price where he served as Division Head and member of the firm’s Operating Steering Committee, Institutional Marketing Steering Committee, Compliance Oversight Committee and member of T. Rowe Price Investment Services Board.
Current board assignments included CureViolence.org, PersonalGenome.org, ABAG (Association of Baltimore Area Grantmakers), Baltimore Corps, Betamore, Fusiform, Citelighter and Calvert Education Services. Past roles include the Chairmanship of the United Way of Central Maryland and the Mutual Fund Education Alliance.
Cammack graduated from Denison University with a bachelor’s degree in history and received his MBA from Columbia University.
James Campbell, M.D., seeks new opportunities to invest in innovative technologies in the areas of therapeutics and devices, and he works with entrepreneurs at the early stages of company formation. Dr. Campbell sits on the boards of Anesiva (NASDAQ: ANSV, an IW portfolio company), Detroit Trading Company, Arcion Therapeutics, and Amplimmune (an IW portfolio company). He is also the Founder and Chairman of the Board of the non-profit organization, the American Pain Foundation.
Campbell has a long record of accomplishment in academic medicine and neuroscience research. He serves as Professor of Neurosurgery and Director of the Blaustein Pain Treatment Center in the Johns Hopkins University School of Medicine, and in the past served as Director of the Residency Training Program for the Department of Neurosurgery at Johns Hopkins. He has served as the chief editor of several books, published well over 100 peer-reviewed research papers, and serves on the editorial board of several academic journals. Campbell has received many national awards for research and public service including the Jacob Javits Neuroscience Investigator Award from the National Institutes of Health, and the Grass Award from the Society of Neurological Surgery. He also has received the Kerr Award for Research from the American Pain Society. He has served as consultant/advisory boards for several biopharmaceutical companies and holds many patents in the life sciences.
Campbell received his bachelor’s degree from the University of Michigan with high honors and high distinction, and his M.D. from Yale University. He completed his residency in Neurosurgery at The Johns Hopkins University, and also pursued post-doctoral training in neurophysiology in the Department of Physiology at Johns Hopkins. Campbell is a diplomat of the American Board of Neurological Surgery.
Arthur (Skip) Colvin is a senior technical executive and serial entrepreneur with a consistent 35+ year record of technical innovation and successful leadership of entrepreneurial product creation and development programs. Colvin has been directly responsible for more than 40 successful products in life science and medical technology from concept to commercialization, and has served in corporate positions ranging from Chief Scientist to CEO.
A graduate of Virginia Polytechnic Institute, Colvin began his career at the startup of Life Technologies (then BRL) while a part time graduate student both at Johns Hopkins APL and the University of Maryland Department of Chemical Engineering. Colvin later founded Cerex Corporation designing and developing products, technologies, and processes for clients as diverse as NIH, Anheuser Busch, the Steeltin Can Corporation, Eli Lilly, Kontes Scientific, New Brunswick Scientific, WR Grace, the National Food Processors, NASA, Life Technologies, Kirkegaard and Perry Laboratories and others.
Most recently Colvin co-founded Sensors for Medicine and Science (now Senseonics) serving as chief scientist to create, design and develop the first ever fully implantable wireless long-term human continuous glucose monitoring system for people with diabetes and helped to raise more than $100 million dollars in venture capital financing. Colvin now has more than 70 U.S. patents, including both issued and pending with approximately 300 foreign counterparts.
AJ Donelson is the principal and co-founder of Advocom Group, a public relations, business development and public affairs firm that helps clients operate at the convergence of business, government, communications and public policy. Prior to Advocom, Donelson led two firms, Dewey Square Group and Ryan McGinn, through hyper growth, culminating in acquisitions by publicly traded global marketing communications companies. Earlier in his career, Donelson headed the Washington office of 3M, responsible for all legislative and regulatory efforts and served on committees and task forces of the National Association of Manufacturers, Chemical Specialties Manufacturers, ECAT and the U.S. Council for International Business. Donelson is an attorney by training, and a Johns Hopkins University alumnus, who recently served on his class reunion committee.
For the past year, Donelson has been helping one of FastForward’s nascent companies, NanoDirect, secure a pilot customer and develop and adhere to multiple milestones.
Richard (Ric) Hughen’s 30 years of professional experience in the life science industry span three startups, a mid-cap and three Fortune 500 companies. He is currently CEO of Cellth Systems, a startup based upon proprietary Circulating Tumor Cell (CTC) analysis technology. Ric’s background crosses diverse clinical fronts including interventional pulmonology, thoracic surgery, interventional cardiology, gastroenterology, ENT, oncology, orthopedics, gynecology, wound care, molecular diagnostics and health-IT. He is founder of Life Science Planning, a strategic consultancy for life science companies with focus on fast paced startup, early stage and emerging growth companies. Hughen was a member of the executive team that led startup CSA Medical from a technology license (Navy), through product development, clinical trials, five FDA clearances, CE mark, four rounds of funding ($50M) and into a profitable commercial business. Before CSA Medical, he directed the marketing efforts for the $210 million molecular diagnostics business of Becton, Dickinson (BD). Prior to BD, Hughen was managing director of an e-learning startup, LearnWare, which was successfully built and sold to a private equity fund. Hughen holds a bachelor’s degree and an MBA from The Pennsylvania State University.
When not working, he is typically outside training for triathlon competition or umpiring Little League baseball.
Anders Jones is an entrepreneur and early-stage tech investor. He is currently CEO at Fabric Wealth, a financial technology company. Jones is also a founding partner at Argyle Ventures, where he led investments in Fixt, emocha, FusiForm and Fabric. Argyle invests in emerging startup markets, with a focus on advertising technology, financial technology and healthcare IT. Prior to Argyle, Jones was on the early team at LiveRamp (acquired by Acxiom for $310 million), and has been involved as an investor or advisor in many other startups in Silicon Valley. Anders has a bachelor’s degree from Stanford University and an MBA from The Wharton School at the University of Pennsylvania.
Jones moved from San Francisco to Baltimore in 2016 to bring his early-stage experience to the vibrant ecosystem here. Over the past six months, Jones has been working with a few FastForward companies, including Corrie Health, which after many many hours of pitch practice was a finalist and won “Best Pitch” at the exclusive UberPitch event in November 2016.
Joseph M. Migliara is a senior level biomedical executive and proven builder of successful fast-growth businesses. He is an experienced CEO and group president of a multinational operating division. Migliara developed and implemented strategies to finance, staff and commercialize products and services for both private and public enterprises. He is deeply experienced in M&A transactions. He co-founded and sold two companies. He also participated at the board and senior management levels in sale of two public companies with a total value of $2 billion and spearheaded acquisition of domestic and foreign companies.
Migliara was the president of North American Operations at NFO World Group from January 1999 to May 2001 and served as its president of consumer and healthcare divisions from September 1997 to January 1999. Migliara joined NFO upon the acquisition of Migliara/Kaplan Associates in January 1996. In 1980, Migliara co-founded Migliara/Kaplan Associates, a strategic market research and consulting firm serving diagnostic, pharmaceutical and biotech clients worldwide. MK completed more than 3,000 client studies focused on new product strategies, pricing, forecast modeling and market segmentation. He was president and CEO from 1980 to 1995.
Migliara began his career at Becton-Dickinson where, as a senior marketing executive, he managed and directed strategic planning for several divisions, directed a rapid succession of new product introductions and helped drive its product lines to worldwide dominance.
He is an investor and board member of VRF Holdings. He was lead independent director of Digene Corp. which was sold to QIAGEN in 2007 for $1.4 billion. He was an investor and director of XLHealth Corporation, a Medicare Advantage insurer targeting diabetic and CHF enrollees. He served as president of the Biomedical Marketing Association. Migliara serves as trustee of Northwest Hospital in Randallstown, Maryland. Migliara holds a bachelor’s degree in economics from The Wharton School at the University of Pennsylvania and an MBA. from Fairleigh Dickinson University.
Michael Richman is currently, president and CEO of NextCure, a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. From 2007 to 2015, and prior to its acquisition by AstraZeneca in 2013, he was president and CEO of Amplimmune when it was a privately held biologics company focused on cancer and autoimmune diseases. From 2002 through 2007, he was the executive vice president and chief operating officer of MacroGenics, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases.
Richman has more than 30 years of experience working in research, intellectual property and business development capacities in companies, such as Chiron Corporation (now Novartis) and MedImmune (prior to AstraZeneca’s acquisition), where he was senior vice president corporate development. While at MedImmune, Richman was responsible for all business development, licensing, intellectual property, legal affairs, project management and strategic planning functions, and drove many significant transactions during that period.
Richman is a member of the board of directors of several public and private companies. Richman obtained his bachelor’s in genetics/molecular biology at the University of California at Davis and his MSBA in international business at San Francisco State University.
For more than 25 years, Daniel J. Roche as advised business and government on the strategic use of technology to improve the value and service of their organizations. Roche is passionate about developing and applying technology to improve the human condition. This vision requires that technology be designed for the intuitive use of humans. Roche enjoys helping startup and early stage companies with their business model, market strategies and product development.
Roche has provided leadership as a founder, co-founder, CEO, executive and board member for numerous startup companies, including: Agile Network Builders (2010), e.magination (2003), Rapid Systems Solutions (1991), Condor Technology Solutions (1998 IPO), Integrated Information Services (1997 IPO), Relevar (2003), I-Connexions, (2003), Graphwise (2005) and e-send (2007).
Roche has received numerous awards including: Baltimore’s Best ‘Turnaround Expert’ by Baltimore Magazine, ‘Small Business Person of the Year’ from the U.S. Department of Commerce Small Business Administration and ‘Entrepreneur of the Year’ from Ernst and Young, as well as the ‘MCI Industry Customer Service Award.’
Roche serves as the entrepreneur in residence for Techfire, a technology incubator serving the Southern Maryland Federal Labs technology transfer activities. He has also served as the ‘Entrepreneur in Residence’ at the University of Maryland, Baltimore County (UMBC) and on the Board of Advisors for the UMBC Technology Center. Roche has taught undergraduate and graduate courses on process and system design, computer architecture, database design, information systems and entrepreneurship.
Roche completed the selective Owner-President Management Program (OPM) at the Harvard Business School (HBS) as well as other executive education courses at Stanford University’s Graduate Business School and the University of Virginia Darden School of Business. He received a master’s degree summa cum laude in computer science from the John Hopkins University Whiting School of Engineering and a bachelor’s degree cum laude in computer science from Central Michigan University. Roche was certified systems professional (CSP) by the Institute for the Certification of Computer Professionals.
MIRs specializing in MII funding*
Dr. Graham Allaway has broad experience in drug discovery, drug development, business development and corporate finance, based on 24 years in the biotechnology industry. He is currently CEO of Cureveda LLC, a spin-out from The Johns Hopkins University. Cureveda is developing compounds that upregulate antioxidant pathways as novel treatments for several inflammatory, autoimmune and neurodegenerative diseases. Allaway is also an Entrepreneur-In-Residence at Johns Hopkins, providing advice on developing and commercializing University inventions.
Prior to joining Cureveda in 2013, Allaway was founding CEO of Celek Pharmaceuticals, a biotech startup focused on the development of in-licensed anti-cancer and anti-inflammatory drugs. Previously, he was founding CEO of Panacos Pharmaceuticals, an antiviral drug discovery and development company. Allaway played a central role in building Panacos from a private venture-backed startup to a public company, while raising more than $125M in private and public equity financing. Before Panacos, he was CEO of Manchester Biotech, a UK biotech incubator, while previously he headed therapeutic R&D at Progenics Pharmaceuticals.
Allaway earned his bachelor’s degree in zoology from Oxford University and his Ph.D. in virology from London University. He was a visiting fellow and visiting associate at the National Institutes of Health before entering the biotechnology business. Allaway has authored more than 40 scientific publications in molecular and cell biology, virology, drug discovery and drug development. He is an inventor on 16 issued and pending U.S. and international patents and has been awarded numerous grants including 10 Small Business Innovative Research Grants from the National Institutes of Health.
Dr. Albine Martin brings more than 20 years of technology commercialization, portfolio management and corporate development experience with three public companies representing the biotechnology, diagnostics, genomics and life sciences sector. She also serves as a member of Active Angels, where she syndicated early stage investments and a member of the independent review panel for NSF Phase1/2. She currently serves as COO at Precision Biologics, a clinical development oncology company with a companion diagnostic program. Precision is a clinical stage oncology company and is advancing its first program for colorectal and pancreatic cancer following the acquisition of assets from Neogenix Oncology.
As vice president at Compugen (CGEN), she built the first consumable products revenue model and alliance management programs to advance both diagnostic and early stage antibody candidates utilizing big data as a discovery platform. During her tenure at Life Technologies [LIFE] she led the creation of multiple new markets and technology platforms to support both the research and emerging genomics segments. She held responsibilities for the global portfolio as Senior Business Director and managed Joint Ventures and geographic expansion within the Asia-Pacific region. She has collaborated with FDA/CBER to develop compliance standards and commercialization strategies for ancillary products within the Cellular Therapy arena. She was also part of the team that led the BLA approval and commercialization of the HPV molecular diagnostic test.
Martin served as member of the startup team at Digene Diagnostics [DIGE] and led the creation of the first revenue generating research based business. Martin holds a Ph.D. from the University of Maryland and served as a staff fellow at the National Institutes of Health and is a graduate of the Program on Leadership and Strategy in Pharmaceuticals and Biotech at the Harvard Business School and holds a certificate of Financial Management from Cornell University. Martin is also an advisory member for organizations like the MIT Enterprise Forum of Washington-Baltimore and BioHealth Innovation Inc. which support translation of technologies towards commercialization.
Bob Storey is the managing director of the Maryland branch of VIC Technology Venture Development, a private, for-profit development firm. At VIC, he assists in the assessment and creation of new ventures, and often serves as the chairman or CEO for newly formed portfolio companies. He is currently chairman/CEO for OsteoVantage, a medical device company focused on osteogenic instrumentation used in spinal fusion procedures, and chairman/CEO for Vixiar Medical, a development company focused on the remote monitoring of chronic cardiopulmonary diseases and disorders.
He concurrently serves as executive in residence for both The Johns Hopkins University and the University of Maryland, supporting the development and commercialization of medical devices and engineering technologies, and is National Faculty for the NSF/NIH I-Corps programs. He is an executive advisor to the Quinn Group, a private family of companies that is focused on the manufacture and worldwide marketing of anesthesia, respiratory, emergency and drug delivery products. Storey serves on the board of directors of Engineered Medical Systems Malaysia SDN BHD, SpeechVive, eMocha and Tanglewood Conservatories.
After earning degrees in chemical engineering and chemistry at the University of Arkansas, Storey joined Exxon Corporation in Houston, where he worked in technology, business planning, mergers and acquisitions. He was an advisor in Exxon’s Corporate Controller organization, held sales and marketing management positions, and led the formation of Exxon Chemical’s international joint venture with Mitsubishi Petrochemical.
In 1994, Storey left Exxon to become vice president and general manager of a privately held engineering company in Maryland. He led the company through a successful sale to Clariant Corporation of Switzerland, where he served as vice president of Clariant’s performance products division.
In 1999, Storey established and led Vapotherm, a Maryland company, as president and CEO. While with the firm, which specializes in non-invasive respiratory devices, he received the U.S. Commerce Department’s Export Achievement Award, the Maryland World Trade Center International Leadership Award and Deloitte’s Technology National Fast 500 award four times.
In the span of 33 years, Di Rienzo’s career in academia, government and industry includes appointments with the Forensic and National Security Sciences Institute at Syracuse University, Blue Highway, RedSky, Welch Allyn, Phillips Medical Systems, Siemens Medical Systems, Honeywell Aerospace and General Dynamics. He’s been recognized twice by Frost & Sullivan as the Medical Device Industry’s Most Valuable Thought Leader, and received their 2015 Catalyst Award for being “a game changer and visionary who has expertise in multiple disciplines and industries.” He was recognized as Technologist of the Year by the Technology Alliance of Central New York. He also received the 2014 Future of Health Technology Award by the Future of Health Technology Institute for “his pioneering work promoting entrepreneurship in the medical and scientific fields.”
Connecting his expertise to community involvement, Di Rienzo served on the inaugural National Biodefense Science Board for both the Bush and Obama Administrations. Additionally, Di Rienzo has spoken to the U.S. Senate Manufacturing Caucus concerning the impact of research and development on manufacturing innovation; participated in a U.S/Northern Ireland economic summit upon request of the Secretary of State; and advised the New York State Economic Task Force on matters of academic and industry collaboration. In April, 2016, Di Rienzo assumed the role of president, CEO & CSO at Voyce – an animal health & wellness company. He is also president & CEO of Radicle Innovation, which is a comprehensive concept to commercialization entity for human and animal health and wellness. Di Rienzo is educated in computer science and forensic science.
Di Rienzo serves as an advisory board member to numerous organizations, including Columbia University Center for Advanced Information Management, Cornell University Biomedical Engineering, Cures Within Reach, Frost & Sullivan, Johns Hopkins Alliance for Science & Technology Development, Rochester Institute of Technology Biomedical Engineering, University of Buffalo Center for Advanced Biomedical & Bioengineering and University City Science Center in Philadelphia as well as a board member to Abram Scientific. He is an active member of the Angel Capital Association Life Science Vetting Committee, and an Inaugural Board Member for Texas Tech University’s Research Park. Di Rienzo is also a member of the American Telemedicine Association, Association for Computing Machinery, Institute of Electrical & Electronics Engineers (Senior Member), and Product Development & Management Association.
Alec Ross is currently a Distinguished Visiting Fellow at The Johns Hopkins University and the author of the New York Times bestseller “The Industries of the Future,” which explores the technological and economic trends and developments that will shape the next 10 years, from cybersecurity and big data to the commercialization of genomics to the code-ification of money, markets and trust.
Ross serves as an advisor to investors, corporations and government leaders to help them understand the implication of factors emerging at the intersection of geopolitics, markets and increasingly disruptive network technologies.
He currently sits on the board of directors or advisors for companies in the fields of technology, media, telecommunications, education, health care and cybersecurity.
Ross recently served for four years as Senior Advisor for Innovation to Secretary of State Hillary Clinton, a role created for him by Secretary Clinton to maximize the potential of technology and innovation in service of America’s diplomatic agenda. In this role, Ross acted as the diplomatic lead on a range of issues including cybersecurity, Internet Freedom, disaster response and the use of network technologies in conflict zones.
Previously, Ross served as the Convener for the Technology, Media & Telecommunications Policy Committee on Barack Obama’s 2008 presidential campaign and served on the Obama-Biden Presidential Transition Team.
In 2000, he and three colleagues co-founded the technology-focused nonprofit organization One Economy and grew it from modest origins in a basement into a global organization serving millions of low-income people, with programs on four continents.
Amita Shukla is an innovator and entrepreneur focused on creating transformative innovations for human health, well-being, and potential. She is the founder and CEO of Vitamita and the author of Enduring Edge: Transforming How We Think, Create and Change. Previously, she spent close to nine years at New Enterprise Associates (NEA), one of the world’s largest and most active venture capital firms, where she evaluated cutting-edge medical innovations, invested in healthcare startups, and worked closely with world-class scientists, physicians, and entrepreneurs. Earlier, she was vice president of AmiKa Corp., a biomedical technology company where she helped develop and market novel research tools—for which she holds 10 issued patents—until its acquisition by Harvard Bioscience. Previously, she founded two startups and was a healthcare analyst at Merrill Lynch. She has written about innovation for publications such as the MIT Technology Review.
Amita regularly advises companies and organizations and speaks to audiences of innovators, entrepreneurs, students, and leaders in industry, academia, and government. In 2010, she was Maryland Governor Martin O’Malley’s youngest appointee to the board of the Technology Development Corporation (TEDCO), a leader in seed/early-stage investing. She was reappointed by Governor Larry Hogan in 2015. Amita has served as a Mentor-in-Residence at Johns Hopkins to help the institution’s scientists and physicians realize the potential of their groundbreaking discoveries and currently serves as the inaugural Pharmapreneur-in-Residence at the University of Maryland School of Pharmacy. She also serves on the boards of Bethesda Green and the Global Liver Institute. Amita holds a BA in biochemistry from Harvard, where she was a senior editor at the Harvard Crimson, and an MBA from Stanford, where she led a team that won the university-wide annual business plan competition for a novel cardiovascular device.
Ben Jealous is an American venture capitalist, civic leader and former president and CEO of the National Association for the Advancement of Colored People (NAACP). He is currently a partner at Kapor Capital, a firm that leverages the tech sector to create progressive social change. He has served as the Board Chairman of the Southern Elections Fund and one of the John L. Weinberg/Goldman Sachs Visiting Professors at Princeton University’s Woodrow Wilson School.
Jealous is currently in the process of moving to Baltimore and is testing the waters in many different neighborhoods. Suggestions and restaurant recommendations are welcome, so long as there are vegetarian options.
Lisa O’Dell Rapuano founded Lane Five Capital Management, a concentrated, long-biased value-oriented hedge fund, in 2006. She ran the fund until year-end 2014 when she returned 90 percent of the capital to partners. She continues to work out several private and controlled positions for the fund. While the fund invested overwhelmingly in liquid, public U.S. equities, during her tenure at Lane Five, she and her team of analysts entered into positions with board representation, private placement debt and liquidations.
From January 2004 to February 2006, Rapuano was the co-chief investment officer of Matador Capital Management, where she managed over half of the $600 million fund on both the long and the short side. After her departure in 2006, Matador closed its funds.
Prior to moving to the hedge fund world, Rapuano managed the Legg Mason Special Investment Trust. As the sole manager from 2001 through 2003, her cumulative returns ranked Special in the top 8 percent of mid-cap core mutual funds. From late 1997 through 2000 she co-managed this fund with Bill Miller. During this period, she also served as the director of research for Bill Miller’s group at Legg Mason Capital Management. Rapuano joined Legg Mason in 1994, and prior to her concurrent responsibilities mentioned above, she was a general analyst for the group.
Rapuano earned the Chartered Financial Analyst (CFA) designation in 1994. She graduated from Yale University with a bachelor’s degree in American studies in 1988, where she was also an All-American swimmer. She lives in Baltimore with her husband and three children.
Peter Chakales is currently serving as COO/EVP of CRE Technologies, leading efforts in the development of cyber solutions and products for the commercial landscape. He participated in the inaugural DreamIT Health round where he served as mentor and is very active within the Baltimore entrepreneurial ecosystem focusing on early stage cyber and life sciences organizations.
Former President/CEO of Performance Technology Group, a Baltimore-based provider of infrastructure engineering and outsourcing service, Chakales founded and led PTG from 1996 through 2009, when it was acquired by WWT. During Chakales’s tenure, PTG grew into a multifaceted organization providing services across commercial, federal and state customers. PTG was recognized as the leading Network Integration firm in the region in 2008. Chakales received the Future 50 SmartCEO and ACG Deal of the Year awards in 2010.
Prior to Performance Technology Group, Chakales served as the manager of global technologies for Black & Decker, where he oversaw all global technology deployments and standards. Chakales led several organizations during his tenure at Black & Decker and implemented the vast majority of technical architectures during the Black & Decker systems replacement activities throughout the early 1990s. Systems deployed included SAP, PeopleSoft, Oracle Financials, I2 and Manugistics.
Before Black & Decker, Chakales was a senior staff member at the Johns Hopkins Bloomberg School of Public Health where he supported a variety of research studies including migraine headache, prospective study of central nervous system function in amateur boxers and the Human Genome Study. Chakales has a bachelor’s degree in biochemistry and molecular biology and a bachelor’s degree in computer science from UMBC.
Dr. Peter Kiener, Ph.D., is the CSO and head of R&D at Sucampo Pharmaceuticals, Inc. He has extensive experience in managing science and business in both large and small company settings, M&A and partnering. He serves on the board of directors and advisory boards in multiple biotech companies. He has deep knowledge and expertise in the development of bio-therapeutics, vaccines and drugs from discovery to regulatory approval. Kiener moved from scientist to director at Bristol Myers Squibb, then moved to Medimmune where he headed global research as EVP.
In 2009, he served as president and CEO of Zyngenia. And from 2013-2014, he hunted for his next gig as an EIR for NEA, landing at Ambrx in San Diego. Peter is a chemist by training, and his real British accent was refined at University of Lancaster and Oxford.
Walter Jin is the co-founder and managing partner of Three Fields Capital and Pacific Healthcare Management, which were established in 2009 and 2012 and based in California. Three Fields Capital is an investment company that provides growth equity and venture capital to healthcare businesses through an evergreen fund with family offices and high net worth individuals. Pacific Healthcare Management is an operating company that provides outsourcing services and solutions to hospitals and health systems, including clinical laboratories, biomedical clinical engineering, revenue cycle management, real estate construction management and IP technology transfer.
Jin is also the chairman and CEO of Pager, an on-demand healthcare technology platform that drives patient engagement and directs care coordination to generate value-based care and outcomes. Patients are connected to nurses through a chat-centric mobile app and triaged to telemedicine consults, house call visits, prescription deliveries, scheduled appointments and ER/UC referrals. Pager’s technology also deploys artificial intelligence on a proprietary data set to power population health management to help change patient behaviors, provider workflows and clinical outcomes.
Jin’s career in healthcare has spanned more than 20 years of investment and operational experience with a track record of investing over $4 billion in more than 60 portfolio companies with only one loss. The majority of his career has been with The Carlyle Group, which grew from $300 million to over $80 billion in assets under management during his tenure. Jin was the co-founder of the Healthcare Group where he invested primarily out of the U.S. buyout funds including Carlyle Partners II, III, IV and V. Jin also worked for the hedge fund SAC Capital as a Healthcare Portfolio Manager and started his career at Salomon Brothers as an investment banking analyst in the mergers and acquisitions Group.
Jin is a graduate of Harvard University with a magna cum laude degree in economics. He also serves as an Innovation Fellows Technical Advisor to the U.S. Department of Health and Human Services.
Vin Singh has 20 years of industry experience including 12 years in senior executive level business and technical roles with cell therapy and stem cell companies. He is currently global director of cell therapy for Thermo Fisher Scientific, where he is responsible for global strategy directed at services for clinical and commercial stage companies, P&L, strategy and capabilities. He is also the founder and BOD member of Next Healthcare, Inc., a pioneering consumer facing regenerative medicine services business.
Prior to that, Singh served as the president, CEO and director of Next Healthcare, Inc. for six years. He was also the co-founder and Director of Engineering for MaxCyte, Inc., a cell therapy systems company. In addition, serving on the starting executive team as the VP Worldwide Business, he helped guide GlobalStem Inc., a stem cell research products and services company, to an early exit. Singh has an MBA with a finance concentration from The Johns Hopkins University, a master’s degree in biomedical engineering from Rensselaer Polytechnic Institute, and a bachelor’s degree in electrical engineering from Rutgers University.